Lantheus Holdings, Inc. reported its financial results for the third quarter of 2025, revealing a revenue of $384.0 million, a slight increase of 1.4% from $378.7 million in the same period last year. However, for the nine months ended September 30, 2025, total revenue decreased by 0.7% to $1.134 billion compared to $1.143 billion in 2024. The company experienced a significant decline in net income, which fell 78.8% to $27.8 million for the quarter, down from $131.1 million in the prior year, and decreased 44.6% to $179.5 million for the nine-month period.
The financial performance was impacted by a notable increase in operating expenses, which surged by 64.9% to $178.8 million for the quarter, primarily due to higher general and administrative costs associated with recent acquisitions, including Evergreen and Life Molecular. Research and development expenses also rose sharply, reflecting the company's ongoing investment in product development. The gross profit for the quarter was $222.4 million, down 8.2% from the previous year, attributed mainly to a decrease in the net sales price of its leading product, PYLARIFY.
Strategically, Lantheus has made significant moves, including the acquisition of Life Molecular Imaging Ltd. for $355.2 million, which is expected to enhance its portfolio in Alzheimer’s disease diagnostics. The company also acquired Evergreen Theragnostics for $276.4 million, further expanding its capabilities in contract development and manufacturing. Additionally, Lantheus announced a definitive agreement to sell its single-photon emission computerized tomography (SPECT) business to SHINE Technologies, which is anticipated to close by the end of the year.
Operationally, Lantheus has seen growth in its Precision Diagnostics segment, particularly with the introduction of Neuraceq, which contributed $20.4 million in revenue since its acquisition. The company reported a total of 1.8 million shares repurchased under its new $400 million share repurchase program, which reflects its commitment to returning value to shareholders. Looking ahead, Lantheus is focused on expanding its market presence and product offerings, with several key regulatory submissions pending, including for LNTH-2501 and MK-6240, both of which have received target action dates from the FDA.
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is a leading provider of radiopharmaceuticals and diagnostic imaging products. Its core activities include developing, manufacturing, and marketing radiopharmaceuticals for oncology and cardiology, such as PYLARIFY and DEFINITY. The company serves healthcare providers worldwide, offering products that improve disease detection, characterization, and patient outcomes through advanced imaging and therapeutic solutions. Its business model combines product sales, strategic partnerships, and clinical development.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.